Combination of Canagliflozin with reduced dose of Sulfonylurea in Japanese type2 diabetic patients

Combination of Canagliflozin with reduced dose of Sulfonylurea in Japanese type2 diabetic patients - CCSJ

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022718

Enrollment

Registered

2016-06-15

Start date

2014-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type2 diabetes

Interventions

At the beginning of the study, the dose of previously prescribed SU, irrespective of the type and dose, was reduced by half and concomitant administration of canagliflozin 100mg/day was initiated.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: age range 20-80 years; type 2 diabetes treated with SU for >12 weeks; and HbA1c >6.5 and <9.0 at screening.

Exclusion criteria

Exclusion criteria: estimated glomerular filtration rate (eGFR) <45 ml/min/1.73 m2 (using the MDRD equation); acute coronary syndrome, stroke, or transient ischemic attack within 3 months prior to consent; severe liver dysfunction.

Design outcomes

Primary

Measure	Time frame
HbA1c, glycoalbumin, FPG, and daily profile of blood glucose and glycemic variability evaluated by CGMs	—

Secondary

Measure	Time frame
weight, systolic BP, diastolic BP, HOMA-R, HOMA-beta, fasting CPR index, LDL-cholestrrol , HDL-cholestrrol, triglyceride, free fatty acid, hematocrit, creatinine, uric acid, urine ketone body, blood ketone body, urinary sediment, and CRP	—

Countries

Japan

Contacts

Public ContactMayuko Harada

Yodogawa Christian Hospital Division of Diabetes and Endocrinology

kfmayuko4621@gmail.com+81-6-6322-2250

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026